FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Vashing | ton. D |).C. 2 | 20549 |
|---------|--------|--------|-------|

| STATEMENT (| OF CH | ANGES | IN BEN | NEFICIAL | OWNERSH | ΗP |
|-------------|-------|-------|--------|----------|---------|----|
| | | | | | | |

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Kelley Robert J. | | | | 2. Issuer Name and Ticker or Trading Symbol Talis Biomedical Corp [TLIS] | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | |
|--|---|--|--|---|--|----------|-------------------------------------|---|--|-------------------|---|---|---------------------|---|---|--------------------|---|---------------------------------------|
| Kelley | Robert . | <u>-</u> | | - | uno. | Diomic | <u> </u> | <u> </u> | 111 | . J | | | X | Director | | | 10% Ow | ner |
| (Last) | | First) | (Middle) | | Date of Earliest Transaction (Month/Day/Year) | | | | | | | X | Officer (below) | give title | | Other (s below) | pecify | |
| C/O TAL | IS BIOM | EDICAL CORPO | RATION | 0 | 06/01/2022 | | | | | | | Chief Executive Officer | | | | | | |
| 230 CON | ISTITUTI | ON DRIVE | | | | | | | | | | | | | | | | |
| | | | | 4 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable | | | | | | |
| (Street) | | | | | | | | | | | | | Line) | Form fil | ed by One | Dano | rting Person | |
| MENLO | PARK | CA | 94025 | | | | | | | | | | Λ | | • | | One Report | |
| | | | | | | | | | | | | | | Person | ca by More | o triuri | One Repon | 9 |
| (City) | (| State) | (Zip) | | | | | | | | | | | | | | | |
| | | Та | ble I - Non- | Derivati | ve S | ecuritie | s Acq | quired, | Disp | osed c | of, or Be | enefic | ially | Owned | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date | | | | Execution Date, Transaction Disposed Of (D | | | | es Acquired (A) or Of (D) (Instr. 3, 4 and | | | | 6. Ownership Form: Direct | | 7. Nature of Indirect | | | | |
| (Month/E | | | | Month/Day | ay/Year) if any (Month/Day/ | | ay/Year) | Code (Instr. 8) | | | | ollowing (l) (l | | nstr. 4) (| Beneficial Ownership | | | |
| | | | | | | | | Code | v | Amount (A) or (D) | | Pri | ice | | nsaction(s) tr. 3 and 4) | | [| Instr. 4) |
| | | | Table II - D | erivativ | e Sec | curities | Acqu | ired, D | ispo | sed of | or Ber | eficia | IIv O | wned | | | | , |
| | | | | .g., put | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Da if any (Month/Day/Y | Code | 5. Numb Derivati Securiti Acquire or Disp of (D) (I 3, 4 and | | re E s (I (A) sed str. | Expiration | Date Exercisable and Expiration Date Month/Day/Year) | | 7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4) | | | 8. Price of Derivative Security (Instr. 5) | 9. Number o derivative Securities Beneficially Owned Following Reported Transaction(| e s lly | Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | | Date Exercisabl | | xpiration ate | Title | Amou or Numb of Sha | er | | (Instr. 4) | | | |
| Stock Option (right to buy) | \$1.03 | 06/01/2022 | | A | | 723,560 | | (1)(2)(3) | 0: | 5/31/2032 | Common Stock | 723,: | 560 | \$0.00 | 723,56 | 50 | D | |

- 1. 1/3 of awards vest as follows: 25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date of June 1, 2022 (VCD) and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.
- 2. 1/3 of the shares shall vest on the seventh anniversary of the VCD, subject to optionholder's continuous service as of such date, provided that such vesting shall be subject to acceleration based upon certain predetermined commercial and regulatory milestones.
- 3. 1/3 of the shares shall vest on the seventh anniversary of the VCD, subject to optionholder's continuous service as of such date, provided that such vesting shall be subject to partial or full acceleration based on pre-determined closing prices of the Company's common stock sustained for a certain number of consecutive trading days.

Remarks:

/s/ J. Roger Moody, Jr., Attorney-in-Fact for Robert J.

06/02/2022

<u>Kelley</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.